# v4.27

## Related releases

## Data changes

### Gene

```
DIS3L2 Background Updated
DIS3L2 Summary Updated
ERCC6 Background Updated
ERCC6 Summary Updated
FANCB Background Updated
FANCB Summary Updated
MTHFR Background Updated
MTHFR Summary Updated
NFATC2 Background Updated
NFATC2 Summary Updated
TMEM127 Background Updated
```

### Alteration

```
BRCA1 D1692N, Mutation Effect, Description Updated
BRCA1 C1787S, Mutation Effect, Description Updated
BRCA1 A1823T, Mutation Effect, Description Updated
BRCA1 I26N, Mutation Effect, Description Updated
BRCA1 I26N, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Inconclusive
BRCA1 I26N, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
BRCA1 C39R, Mutation Effect, Description Updated
BRCA1 C39R, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Inconclusive
BRCA1 C39R, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
BRCA1 C47F, Mutation Effect, Description Updated
BRCA1 C47F, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Inconclusive
BRCA1 C47F, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
BRCA1 S770L, Mutation Effect, Description Updated
BRCA1 S770L, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA1 S770L, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA1 S770L Added
BRCA1 E1559K, Mutation Effect, Description Updated
BRCA1 E1559K, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
BRCA1 E1559K, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
BRCA1 E1559K Added
BRCA1 E1559Q, Mutation Effect, Description Updated
BRCA1 E1559Q, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old:
BRCA1 E1559Q, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
BRCA1 E1559Q Added
BRCA1 K1759N, Mutation Effect, Description Updated
BRCA1 K1759N, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA1 K1759N, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA1 K1759N Added
BRCA2 V159M, Mutation Effect, Description Updated
BRCA2 V159M, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Inconclusive
BRCA2 V159M, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
BRCA2 K1530N, Mutation Effect, Description Updated
BRCA2 K1530N, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 K1530N, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 K1530N Added
BRCA2 T2412I, Mutation Effect, Description Updated
BRCA2 T2412I, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA2 T2412I, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA2 T2412I Added
BRCA2 A2911E, Mutation Effect, Description Updated
BRCA2 A2911E, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA2 A2911E, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA2 A2911E Added
BRCA2 N3187K, Mutation Effect, Description Updated
BRCA2 N3187K, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
BRCA2 N3187K, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
BRCA2 N3187K Added
BRCA2 D23Y, Mutation Effect, Description Updated
BRCA2 D23Y, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 D23Y, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 D23Y Added
BRCA2 Y600C, Mutation Effect, Description Updated
BRCA2 Y600C, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
BRCA2 Y600C, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old:
BRCA2 Y600C Added
EGFR R669Q Demoted
POLE G6R, Mutation Effect, Description Updated
POLE G6R, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Loss-of-function
POLE G6R, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely
RET V648I, Mutation Effect, Description Updated
RET V648I, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Gain-of-function
RET V648I, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely
ROS1 L2086F, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old:
SF3B1 E592K, Mutation Effect, Description Updated
SF3B1 E592K, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old:
SF3B1 E592K, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
SF3B1 E592K Added
SF3B1 E902K, Mutation Effect, Description Updated
SF3B1 E902K, Mutation Effect, Effect Updated
	 New: Likely Switch-of-function
	 Old:
SF3B1 E902K, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
SF3B1 E902K Added
TP53 R273G, Mutation Effect, Description Updated
TP53 R273G, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old: Inconclusive
TP53 R273G, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old: Inconclusive
TP53 R156C, Mutation Effect, Description Updated
TP53 R156C, Mutation Effect, Effect Updated
	 New: Inconclusive
	 Old: Likely Loss-of-function
TP53 R156C, Mutation Effect, Oncogenic Updated
	 New: Inconclusive
	 Old: Likely
TP53 V157I, Mutation Effect, Description Updated
TP53 V157I, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
TP53 V157I, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
TP53 V157I Added
TP53 A276V, Mutation Effect, Description Updated
TP53 A276V, Mutation Effect, Effect Updated
	 New: Likely Neutral
	 Old:
TP53 A276V, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
TP53 A276V Added
VHL M54_D213trunc, Mutation Effect, Description Updated
VHL M54_D213trunc Name Changed
	 New: M54_D213trunc
	 Old: Truncating Mutations
VHL 54_213trunc Name Changed
	 New: 54_213trunc
	 Old: M54_D213trunc
VHL M54_D213trunc Name Changed
	 New: M54_D213trunc
	 Old: 54_213trunc
```

### Evidence

```
AKT1 E17K, Endometrial Cancer, Ovarian Cancer, Capivasertib, Description Updated
BRAF L597, Melanoma, Trametinib, Description Updated
BRAF Fusions, Melanoma, Trametinib, Cobimetinib, Description Updated
BRAF V600, Erdheim-Chester Disease, Vemurafenib, Description Updated
BRAF V600, Langerhans Cell Histiocytosis, Vemurafenib, Dabrafenib, Description Updated
BRAF V600, Histiocytosis, Vemurafenib, Dabrafenib, Description Updated
BRAF V600E, Biliary Tract, Hepatobiliary Cancer Name Changed
	 New: Biliary Tract, Hepatobiliary Cancer
	 Old: Biliary Tract Cancer, NOS
BRCA1 Oncogenic Mutations, Ovarian Cancer, Peritoneal Serous Carcinoma, Ovary, Fallopian Tube, Rucaparib, Description Updated
BRCA1 Oncogenic Mutations, Breast Cancer, Olaparib, Description Updated
BRCA1 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Olaparib, Description Updated
BRCA1 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Rucaparib, Description Updated
BRCA1 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Talazoparib + Enzalutamide, Description Updated
BRCA1 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Niraparib + Abiraterone Acetate + Prednisone, Description Updated
BRCA2 Oncogenic Mutations, Ovarian Cancer, Peritoneal Serous Carcinoma, Ovary, Fallopian Tube, Rucaparib, Description Updated
BRCA2 Oncogenic Mutations, Breast Cancer, Olaparib, Description Updated
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Olaparib, Description Updated
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Rucaparib, Description Updated
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Olaparib + Abiraterone + Prednisone, Description Updated
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Talazoparib + Enzalutamide, Description Updated
BRCA2 Oncogenic Mutations, Prostate Cancer, Prostate Cancer, NOS, Niraparib + Abiraterone Acetate + Prednisone, Description Updated
DIS3L2 Gene Type, Oncogene Updated
DIS3L2 Gene Type, Tumor Suppressor Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Poziotinib, Description Updated
EGFR 762_823ins [Exon 20 in-frame insertions], Non-Small Cell Lung Cancer, Zipalertinib, Description Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Summary Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib, Description Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib, Level Updated
	 New: 4
	 Old:
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Neratinib 4 Added
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan, Description Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan, Level Updated
	 New: 4
	 Old:
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Trastuzumab Deruxtecan 4 Added
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab, Description Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab, Level Updated
	 New: 4
	 Old:
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Biliary Tract Added
ERBB2 Oncogenic Mutations, Biliary Tract, Pertuzumab + Trastuzumab 4 Added
ERBB2 Amplification, Esophagogastric Cancer, Pembrolizumab + Trastuzumab + Chemotherapy, Description Updated
ERBB2 Oncogenic Mutations, Breast Cancer, Summary Updated
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant, Description Updated
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant, FDA Level Updated
	 New: Fda3
	 Old: no
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant, Level Updated
	 New: 2
	 Old:
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant, Propagation to Other Liquid Tumor Types Updated
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant, Propagation to Other Solid Tumor Types Updated
ERBB2 Oncogenic Mutations, Breast Cancer, Neratinib + Trastuzumab + Fulvestrant 2 Added
ERBB2 Oncogenic Mutations, Biliary Tract, Hepatobiliary Cancer Name Changed
	 New: Biliary Tract, Hepatobiliary Cancer
	 Old: Biliary Tract
ERBB2 Amplification, Biliary Tract, Hepatobiliary Cancer Name Changed
	 New: Biliary Tract, Hepatobiliary Cancer
	 Old: Biliary Tract Cancer, NOS
ERCC6 Gene Type, Oncogene Updated
MDM2 Amplification, Biliary Tract, Hepatobiliary Cancer Name Changed
	 New: Biliary Tract, Hepatobiliary Cancer
	 Old: Biliary Tract Cancer, NOS
NF1 Oncogenic Mutations, Neurofibroma, Summary Updated
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib, Description Updated
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib, FDA Level Updated
	 New: Fda2
	 Old: no
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib, Level Updated
	 New: 1
	 Old:
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib, Propagation to Other Liquid Tumor Types Updated
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib, Propagation to Other Solid Tumor Types Updated
NF1 Oncogenic Mutations, Neurofibroma, Mirdametinib 1 Added
NFATC2 Gene Type, Oncogene Updated
NFATC2 Gene Type, Tumor Suppressor Updated
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Summary Updated
NPM1 Oncogenic Mutations, Acute Myeloid Leukemia, Revumenib, Description Updated
RARA Fusions, APL with PML-RARA, Prognostic Summary Updated
TP53 Y220C, All Solid Tumors, Rezatapopt, Description Updated
```
